BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 11750244)

  • 1. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
    J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [5 alpha-reductase and prostate].
    Lobaccaro JM; Boudon C; Lumbroso S; Lechevallier E; Mottet N; Rebillard X; Sultan C
    Ann Endocrinol (Paris); 1997; 58(5):381-92. PubMed ID: 9685996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
    di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
    Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
    Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
    Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
    Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5α-reductase type 3 enzyme in benign and malignant prostate.
    Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
    Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.
    Godoy A; Kawinski E; Li Y; Oka D; Alexiev B; Azzouni F; Titus MA; Mohler JL
    Prostate; 2011 Jul; 71(10):1033-46. PubMed ID: 21557268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
    Délos S; Carsol JL; Fina F; Raynaud JP; Martin PM
    Int J Cancer; 1998 Mar; 75(6):840-6. PubMed ID: 9506528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
    Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
    Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of 5-alpha-reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms].
    Wirth MP; Helke C; Froschermaier SE
    Urologe A; 1997 Jan; 36(1):35-9. PubMed ID: 9123679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
    Pais P
    Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of 5α-reductase inhibitors in benign prostatic diseases.
    Azzouni F; Mohler J
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.